ReviewFrontiers in pain research (Lausanne, Switzerland)2026
Pain and sensory abnormalities in prodromal and early Parkinson's disease: mechanisms, assessment, and clinical implications.
Review in Frontiers in pain research (Lausanne, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is traditionally characterized by motor symptoms; however, non-motor symptoms, particularly pain and sensory disturbances, are increasingly recognized as potential early manifestations that precede motor onset. Pain has been reported in up to 59% of patients before the onset of motor symptoms and in up to 72% in the early stages of PD, yet its underlying mechanisms and clinical implications remain insufficiently understood. Emerging evidence suggests that dopaminergic dysfunction may alter nociceptive processing across both peripheral and central pathways, involving changes within spinal, brainstem, and cortical pain networks. Despite this, the heterogeneity of pain phenotypes and the lack of standardized assessment approaches continue to limit the diagnostic and clinical utility of pain as an early disease indicator. Importantly, early pain symptoms may lead to misinterpretation and unnecessary investigations, potentially delaying PD diagnosis. This narrative review critically examines four key aspects of pain in prodromal to early-stage PD: (1) pain as an early clinical feature, (2) underlying nociceptive and neurodegenerative mechanisms, (3) alterations in small-fiber function assessed by quantitative sensory testing, and (4) large-fiber involvement evaluated through nerve conduction studies. By integrating current evidence, this review highlights the role of pain as a potential early indicator of PD, synthesizes current knowledge on sensory dysfunction across the prodromal to early disease spectrum, and identifies key gaps to support diagnosis, improved patient stratification, and mechanism-based management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.